MYGN - Myriad Genetics, Inc.
| Previous Close | 25.99 |
| Open | 25.74 |
| Bid | 23.11 x 1800 |
| Ask | 25.98 x 3200 |
| Day's Range | 23.52 - 26.24 |
| 52 Week Range | 23.08 - 50.44 |
| Volume | 1,421,187 |
| Avg. Volume | 886,473 |
| Market Cap | 1.762B |
| Beta (3Y Monthly) | 1.33 |
| PE Ratio (TTM) | 85.44 |
| EPS (TTM) | 0.28 |
| Earnings Date | Aug 19, 2019 - Aug 23, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.00 |
- Markit•3 days ago
See what the IHS Markit Score report has to say about Myriad Genetics Inc.
Myriad Genetics Inc NASDAQ/NGS:MYGNView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $984 million over the last one-month into ETFs that hold MYGN are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Bloomberg•4 days ago
Corporations Shouldn't Be Able to Patent Your DNA
Author Michael Crichton warned of the evils of gene patents in his 2006 novel “Next” and, more directly, in a 2007 New York Times commentary piece. Crichton’s concern about giving exclusive legal rights to the use of information about human bodies was a matter of principle: “You can’t patent snow, eagles or gravity, and you shouldn’t be able to patent genes, either. If one company develops a genetic test for a disease, for example, a patent on the gene involved might prevent scientists at a different institution from seeking possible gene therapies for the disease.
- Zacks•10 days ago
Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•11 days ago
AngioDynamics Divests NAMIC Portfolio to Medline Industries
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
- Zacks•11 days ago
Myriad Genetics Announces Study Results Of myRisk Cancer Test
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
- GlobeNewswire•11 days ago
Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference
SALT LAKE CITY, June 05, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone,.
- Motley Fool•12 days ago
Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May
Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.
- Zacks•13 days ago
Myriad Genetics' (MYGN) POLO Study Shows Positive Results
Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.
- GlobeNewswire•13 days ago
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology
SALT LAKE CITY, June 03, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two.
- GlobeNewswire•14 days ago
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)
“Our long-standing collaboration with Myriad Genetics Inc. has enabled us to deliver the positive POLO study in pancreatic cancer patients, demonstrating our shared ambition to target precision medicines to the right patients across different cancers,” said Ruth March, Ph.D., senior vice president and head of Precision Medicine, Oncology R&D, AstraZeneca.
- Simply Wall St.•17 days ago
Is Myriad Genetics, Inc.'s (NASDAQ:MYGN) CEO Salary Justified?
Mark Capone has been the CEO of Myriad Genetics, Inc. (NASDAQ:MYGN) since 2015. First, this article will compare CEO...
- Zacks•26 days ago
Why Should You Hold on to Myriad Genetics (MYGN) Stock?
Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).
- Motley Fool•last month
Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?
The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.
- GlobeNewswire•last month
Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting
SALT LAKE CITY, May 14, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at.
- Thomson Reuters StreetEvents•last month
Edited Transcript of MYGN earnings conference call or presentation 7-May-19 8:30pm GMT
Q3 2019 Myriad Genetics Inc Earnings Call
- GlobeNewswire•last month
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that the EndoPredict® test (EPclin) identifies women with early-stage breast cancer who can safely forgo extended endocrine therapy five years after diagnosis. Findings from the study were published in the journal Clinical Cancer Research.
- Motley Fool•last month
Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today
These stocks struggled on a mixed day on Wall Street.
Motley Fool•last monthMyriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript
MYGN earnings call for the period ending March 31, 2019.
- Zacks•last month
Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
- Zacks•last month
Myriad Genetics (MYGN) Beats Q3 Earnings Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Myriad: Fiscal 3Q Earnings Snapshot
On a per-share basis, the Salt Lake City-based company said it had profit of 9 cents. Earnings, adjusted for one-time gains and costs, came to 46 cents per share. The results topped Wall Street expectations. ...
- GlobeNewswire•last month
Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results
Total Third-Quarter Revenues of $216.6 Million, Up 18 PercentThird-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 -- Myriad.
